Efficacy and Safety of Bupivacaine Liposomal in Intercostal Nerve Block for Postoperative Pain Management Following Uniportal Thoracoscopy: A Randomized Trial
Pain Research and Management · 2025
DOI: 10.1155/prm/8816879 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pain Research and Management, 2025. Verfasst von Lingjun Dong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shaoxing People's Hospital, 568-Zhongxing North Road, Shaoxing 312000, Zhejiang, China. Hauptthemen laut MEDLINE: Postoperative Pain, Bupivacaine, Nerve Block, Anesthetics, Local. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schmerzmanagement
Abstract (Originalsprache)
Background
Postoperative pain in thoracic surgery often requires opioids, yet can be poorly managed with short‐acting anesthetics. Liposomal bupivacaine (LB) offers prolonged analgesia, potentially improving pain control and reducing opioid use. This study evaluates LB’s effectiveness and safety in thoracic postoperative pain management, aiming to provide an alternative to current practices.
Methods
In this single‐center, double‐blind, prospective, randomized controlled trial, patients undergoing uniportal lobectomy, segmentectomy, or wedge resection from November 2023 to May 2024 were enrolled. Participants were randomly assigned in a 1:1 ratio to receive either 0.375% ropivacaine (control group, n = 57) or LB (LB group, n = 56) for intercostal nerve blocks (ICNBs). Postoperative visual analog scale (VAS) scores, opioid consumption, overall benefit of analgesia score (OBAS), chest tube duration, length of hospital stay, and adverse events (AEs) were recorded and analyzed.
Results
Data from 57 patients in the control group and 56 patients in the LB group were included in the analysis, with no significant demographic differences between the groups. The LB group demonstrated lower VAS scores at rest and during activity ( p > 0.05), reduced opioid consumption ( p = 0.021), and higher OBAS ( p < 0.01) compared with the control group. No significant differences were observed in chest tube duration, length of hospital stay, or AEs between the groups.
Conclusion
LB is safe and effective for ICNB, providing significant postoperative pain relief for patients undergoing uniportal thoracoscopic surgery. Trial Registration: Chinese Registry of Clinical Trials: chiCTR2300075463
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Shaoxing People's Hospital, 568-Zhongxing North Road, Shaoxing 312000, Zhejiang, China.
- Department of Anesthesiology, Shaoxing People's Hospital, 568-Zhongxing North Road, Shaoxing 312000, Zhejiang, China.
- Department of Nursing, Shaoxing People's Hospital, 568-Zhongxing North Road, Shaoxing 312000, Zhejiang, China.
ORCID-Profile: Lingjun Dong, Xiang Wang, Linhai Fu, Zongming Jiang, Yulong Wang, Aixia Chen, Jianyi Ding, Guangmao Yu
Zitieren
APA
Dong, L., Wang, X., Fu, L., Jiang, Z., Wang, Y., Chen, A., Ding, J., & Yu, G. (2025). Efficacy and Safety of Bupivacaine Liposomal in Intercostal Nerve Block for Postoperative Pain Management Following Uniportal Thoracoscopy: A Randomized Trial. Pain Research and Management. https://doi.org/10.1155/prm/8816879
Vancouver
Dong L, Wang X, Fu L, Jiang Z, Wang Y, Chen A, et al. Efficacy and Safety of Bupivacaine Liposomal in Intercostal Nerve Block for Postoperative Pain Management Following Uniportal Thoracoscopy: A Randomized Trial. Pain Research and Management. 2025. doi:10.1155/prm/8816879
BibTeX
@article{Dong2025,
author = {Dong, Lingjun and Wang, Xiang and Fu, Linhai and Jiang, Zongming and Wang, Yulong and Chen, Aixia and Ding, Jianyi and Yu, Guangmao},
title = {Efficacy and Safety of Bupivacaine Liposomal in Intercostal Nerve Block for Postoperative Pain Management Following Uniportal Thoracoscopy: A Randomized Trial},
journal = {Pain Research and Management},
year = {2025},
doi = {10.1155/prm/8816879}
}
EUVIMED